OBJECTIVE: The serum C-reactive protein (CRP) concentration is commonly used in rheumatoid arthritis (RA) as a surrogate marker of systemic inflammation, presumably induced by synovitis. However, other tissues, such as adipose tissue, can induce CRP production. This study was undertaken to explore the associations between measures of adiposity and CRP levels in RA. METHODS: One hundred ninety-six men and women with RA underwent anthropometric assessment and total body dual-energy x-ray absorptiometry for measurement of total and regional body fat and lean mass. The associations between measures of fat and lean mass and serum levels of CRP and interleukin-6 (IL-6) were determined in analyses stratified by sex, with adjustment for pertinent demographic, lifestyle, and RA disease and treatment covariates as well as for the potential modifying effects of articular activity and biologic pharmacotherapeutic agents. RESULTS: All measures of adiposity were significantly associated with the level of CRP in women, but not in men. In women, the measure of adiposity that showed the strongest association with the CRP level was truncal fat, in which, in adjusted analyses, each kilogram increase was associated with a 0.101-unit increase in the logarithmically transformed CRP level (P < 0.001). Neither the level of articular activity nor the use of biologic agents significantly modified this association in women. However, in men, elevated articular involvement was associated with a decreasing CRP level as truncal fat increased. For all analyses, substitution of IL-6 for CRP produced similar findings. CONCLUSION: Adiposity is independently associated with CRP levels in women with RA, and thus may confound the estimation of RA disease activity when serum CRP concentration is used as a surrogate for systemic inflammation.
OBJECTIVE: The serum C-reactive protein (CRP) concentration is commonly used in rheumatoid arthritis (RA) as a surrogate marker of systemic inflammation, presumably induced by synovitis. However, other tissues, such as adipose tissue, can induce CRP production. This study was undertaken to explore the associations between measures of adiposity and CRP levels in RA. METHODS: One hundred ninety-six men and women with RA underwent anthropometric assessment and total body dual-energy x-ray absorptiometry for measurement of total and regional body fat and lean mass. The associations between measures of fat and lean mass and serum levels of CRP and interleukin-6 (IL-6) were determined in analyses stratified by sex, with adjustment for pertinent demographic, lifestyle, and RA disease and treatment covariates as well as for the potential modifying effects of articular activity and biologic pharmacotherapeutic agents. RESULTS: All measures of adiposity were significantly associated with the level of CRP in women, but not in men. In women, the measure of adiposity that showed the strongest association with the CRP level was truncal fat, in which, in adjusted analyses, each kilogram increase was associated with a 0.101-unit increase in the logarithmically transformed CRP level (P < 0.001). Neither the level of articular activity nor the use of biologic agents significantly modified this association in women. However, in men, elevated articular involvement was associated with a decreasing CRP level as truncal fat increased. For all analyses, substitution of IL-6 for CRP produced similar findings. CONCLUSION: Adiposity is independently associated with CRP levels in women with RA, and thus may confound the estimation of RA disease activity when serum CRP concentration is used as a surrogate for systemic inflammation.
Authors: S N Blair; W L Haskell; P Ho; R S Paffenbarger; K M Vranizan; J W Farquhar; P D Wood Journal: Am J Epidemiol Date: 1985-11 Impact factor: 4.897
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Marie-Eve Piché; Simone Lemieux; Stanley John Weisnagel; Louise Corneau; André Nadeau; Jean Bergeron Journal: Am J Cardiol Date: 2005-07-01 Impact factor: 2.778
Authors: R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg Journal: J Clin Invest Date: 1994-06 Impact factor: 14.808
Authors: D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot Journal: Arthritis Rheum Date: 1993-06
Authors: Pedro L Furlam; Mariana O Perez; Andre S Franco; Valeria F Caparbo; Samuel K Shinjo; Rosa M R Pereira Journal: Clin Rheumatol Date: 2021-01-23 Impact factor: 2.980
Authors: James S Andrews; Laura Trupin; Gabriela Schmajuk; Jennifer Barton; Mary Margaretten; Jinoos Yazdany; Edward H Yelin; Patricia P Katz Journal: Arthritis Care Res (Hoboken) Date: 2015-08 Impact factor: 4.794
Authors: Robert R Edwards; Jon Giles; Clifton O Bingham; Claudia Campbell; Jennifer A Haythornthwaite; Joan Bathon Journal: Pain Med Date: 2010-03-04 Impact factor: 3.750
Authors: D Jawaheer; J Olsen; M Lahiff; S Forsberg; J Lähteenmäki; I G da Silveira; F A Rocha; I M Magalhães Laurindo; L M Henrique da Mota; A A Drosos; E Murphy; C Sheehy; E Quirke; M Cutolo; S Rexhepi; J Dadoniene; S M M Verstappen; T Sokka Journal: Clin Exp Rheumatol Date: 2010-08-30 Impact factor: 4.473
Authors: James S Andrews; Laura Trupin; Gabriela Schmajuk; Jennifer Barton; Mary Margaretten; Jinoos Yazdany; Edward H Yelin; Patricia P Katz Journal: Arthritis Care Res (Hoboken) Date: 2015-01 Impact factor: 4.794